3P Biopharmaceuticals appoints Ricardo Izquierdo as Quality Director

3P Biopharmaceuticals appoints a new member to the management team with the incorporation of Ricardo Izquierdo as Quality Director.

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, appoints a new member to the management team with the incorporation of Ricardo Izquierdo as Quality Director.

3P Biopharmaceuticals appoints Ricardo Izquierdo as Quality Director, leading quality control, quality assurance and analytical departments

Ricardo Izquierdo has a solid experience as a quality director and joins 3P Biopharmaceuticals with the aim of encompassing and monitoring the entire quality chain in the company.

He has spent over 30 years working in leadership positions within Quality Assurance and Quality Control departments in companies such as Famar Healthcare Services, Crucell, Lapis Lazuli International, Avizor, Inmunotek, Inmunal and Unolab Manufacturing.

He brings with him a strong background in Quality within the pharmaceutical industry having served as a Qualified Person, Manager, and Head of Quality in various Quality Control and Quality Assurance organizations.

He began his career in 1990 at Inmunal as a Quality Director and since then he has not stopped developing his knowledge and skills in the field of Pharmaceutical Quality.

Therefore, his professional career has been developed in GMP environments, and he is an expert in design, development and implementation of Pharmaceutical Quality systems, as well as in the management and obtaining of Medicines Licences (MAH).

He also has expertise; among others, in sterile medicine manufacturing, implementation of quality standards, and biological products for human use (vaccines).
Before joining the 3P team, he was Head of Quality at Famar.

I am grateful for the opportunity to continue building and developing a full quality strategy that allows 3P to advance its position as the leading CDMO in Europe” said Ricardo upon arrival at the Noain-based company.

Dámaso Molero, CEO at 3P Biopharmaceuticals said: “We are very pleased to welcome Ricardo Izquierdo to our team. His great experience as a quality manager will help us lead the entire 3P quality process and provide the best CDMO service in the market“.

Therefore, with this new addition to the management team,3P Biopharmaceuticals continues its growth plan and consolidates a competitive position as one of the leading CDMOs in Europe.

View the full press release here

Our dedicated team of specialists will be happy to discuss any of your CDMO supply chain needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis.

Published: 19th September 2023
Toleranzia is at the forefront of innovation with their groundbreaking candidate, TOL2, designed to address the autoimmune neuromuscular disease, Myasthenia Gravis (MG).
Read more

3P Biopharmaceuticals lands in the United States.

Published: 8th June 2023
The Navarre biological CDMO inaugurates its first commercial office in Boston, supported by Keensight Capital.
Read more

3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.

Published: 2nd May 2023
The process transfer and GMP supply of the FGF-1 candidate have been achieved successfully by both companies.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.